ifosfamide has been researched along with Distorted Hearing in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The patients were treated between 1/1/1998 and 6/30/1999 according to the sarcoma protocols COSS-96, CWS-96, and EICESS-92, the median cumulative doses of the focussed drugs were for cisplatin: 360 mg/m(2), for doxorubicin: 270 mg/m(2), and for ifosfamide: 24 g/m(2)." | 5.11 | Late effects surveillance system for sarcoma patients. ( Beck, JD; Bielack, S; Langer, T; Paulussen, M; Stöhr, W; Treuner, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Langer, T | 1 |
| Stöhr, W | 1 |
| Bielack, S | 1 |
| Paulussen, M | 1 |
| Treuner, J | 1 |
| Beck, JD | 1 |
| Meyer, WH | 1 |
| Ayers, D | 1 |
| McHaney, VA | 1 |
| Roberson, P | 1 |
| Pratt, CB | 1 |
1 trial available for ifosfamide and Distorted Hearing
| Article | Year |
|---|---|
Late effects surveillance system for sarcoma patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Cisplatin; Doxorubicin; Feasibili | 2004 |
1 other study available for ifosfamide and Distorted Hearing
| Article | Year |
|---|---|
Ifosfamide and exacerbation of cisplatin-induced hearing loss.
Topics: Antineoplastic Combined Chemotherapy Protocols; Auditory Threshold; Cisplatin; Drug Synergism; Heari | 1993 |